|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:analysis
|
in progress
|
|
gptkbp:binding_site
|
extracellular domain of HER2
|
|
gptkbp:biological_source
|
engineered cell lines
|
|
gptkbp:can_be_used_to
|
combination therapy
|
|
gptkbp:class
|
targeted therapy
|
|
gptkbp:clinical_trial
|
gptkb:Zymeworks_Inc.
Phase 1
pending
to be determined
collected
progression-free survival
NCT number
various clinical sites
|
|
gptkbp:clinical_trial_phase1
|
ongoing
|
|
gptkbp:collaboration
|
various pharmaceutical companies
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:developed_by
|
gptkb:Zymeworks_Inc.
|
|
gptkbp:development
|
biotech firms
|
|
gptkbp:dosage_form
|
determined in trials
|
|
gptkbp:eligibility
|
specific criteria
|
|
gptkbp:feedback
|
to be assessed
|
|
gptkbp:funding
|
secured funding
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zymeworks' ZW25
|
|
gptkbp:impact
|
potentially significant
|
|
gptkbp:indication
|
gptkb:Oncology
|
|
gptkbp:innovation
|
engineered antibody technology
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investigator_initiated_trial
|
possible
|
|
gptkbp:is_effective_against
|
under investigation
|
|
gptkbp:is_tested_for
|
HER2 expression
|
|
gptkbp:knockouts
|
high affinity for HER2
|
|
gptkbp:market_position
|
not yet marketed
|
|
gptkbp:mechanism_of_action
|
immune-mediated destruction of cancer cells
targeting HER2
|
|
gptkbp:objective
|
evaluate safety and efficacy
|
|
gptkbp:origin
|
humanized
|
|
gptkbp:patient_population
|
HER2-positive patients
|
|
gptkbp:project
|
clinical development
planned for further studies
|
|
gptkbp:publication
|
gptkb:academic_journals
|
|
gptkbp:recruitment
|
active
|
|
gptkbp:regulatory_compliance
|
planned
not approved yet
|
|
gptkbp:research
|
conducted
biopharmaceutical research
|
|
gptkbp:research_areas
|
high
oncology
|
|
gptkbp:research_focus
|
cancer therapeutics
|
|
gptkbp:research_institutes
|
gptkb:Zymeworks_Inc.
|
|
gptkbp:research_output
|
preliminary results
|
|
gptkbp:research_timeline
|
ongoing research efforts
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:safety_measures
|
ongoing
|
|
gptkbp:scientific_goals
|
improve patient outcomes
|
|
gptkbp:service_frequency
|
once every three weeks
|
|
gptkbp:side_effect
|
to be determined
|
|
gptkbp:status
|
investigational
|
|
gptkbp:targets
|
gptkb:HER2
|
|
gptkbp:therapeutic_strategy
|
monotherapy or combination therapy
|
|
gptkbp:type
|
therapeutic antibody
|
|
gptkbp:bfsParent
|
gptkb:Zymeworks_US,_Inc.
|
|
gptkbp:bfsLayer
|
7
|